In a surprising move, Novo Nordisk CEO Lars Fruergaard Jorgensen steps down as the company faces significant market challenges and competition from Eli Lilly's Zepbound. With share prices plummeting, the board seeks new leadership to navigate the turbulent landscape.
Pfizer Inc. has decided to stop the development of its obesity pill, danuglipron, after safety concerns emerged from a clinical trial. This move comes as competition heats up with Novo Nordisk and Eli Lilly's successful weight-loss treatments.
Eli Lilly is set to unveil results from trials of orforglipron, its groundbreaking once-daily obesity pill, potentially revolutionizing weight loss treatment by offering a needle-free alternative. Analysts predict it could capture a significant share of the $150 billion GLP-1 market.
Eli Lilly to invest $27 billion in building new US manufacturing plants amid challenges from drug import duties. The move aligns with Trump's push for American manufacturing revitalization.
Discover how Eli Lilly's $50 billion investment in US manufacturing will create high-wage jobs, advance pharmaceutical innovation, and boost economic growth.
Eli Lilly introduces discounted higher doses of the weight loss drug Zepbound in a move to make the treatment more accessible to uninsured patients and address the growing demand for obesity treatments.
Discover how a new study suggests that Ozempic, a drug commonly used for diabetes and weight loss, may also help reduce alcohol consumption and cravings in individuals with alcohol-use disorder.